Received Jul 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
first dose was administered (July 2, 2024). 2nd dose should have been administered 2 months later in September 2024; No additional AE; 5 ML; This spontaneous report was received from a pharmacist, concerning to a 31-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 02-Jul-2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), 5 mL (5 ML), (lot # and expiration date were not reported), as prophylaxis. (Incorrect dose administered) Since the second dose dose should have been administered 2 months later in September 2024, the doses would not entered in the recommended interval of 13 months. (Inappropriate schedule of product administration). No additional adverse event (No adverse event).